VivoSeq
Immunology

Discoid Lupus Erythematosus

10

Pipeline Programs↗

1

Active Trials↗

10

Companies Involved↗

Discoid Lupus Erythematosus is an early-stage landscape with 10 programs across 10 companies. The most active players are Bristol-Myers Squibb, Incyte, Astion Pharma A/S. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

50/100

Attrition Rate

43/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Incyte logo

Incyte

2 programs

Phase 2A

Astion Pharma A/S

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2I

Immunex

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

11 of 14 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody214%Protein / enzyme17%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed6 · 43%
Terminated4 · 29%
Withdrawn2 · 14%
Recruiting1 · 7%
Unknown status1 · 7%

Clinical Trials

Trial Activity

14 trials

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Recruiting·IInnovaderm Research Inc.·Phase 2·NCT06261021·20 enrolled
A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
Completed·National Cancer Institute (NCI)·Phase 2·NCT00001680·17 enrolled
Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)
Completed·AAstion Pharma A/S·Phase 2·NCT00625157
Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus
Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT00608673·10 enrolled
Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
Completed·UUniversity of Leeds·Phase 2·NCT02656082·25 enrolled
Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
Completed·UUniversity of Rochester·Phase 2·NCT04908280·10 enrolled
Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions
Completed·AAstion Pharma A/S·Phase 2·NCT00625521·32 enrolled
Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
Terminated·Amgen logoAmgen·Phase 1·NCT01164917·16 enrolled
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT01466725·5 enrolled
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
Terminated·LEO Pharma logoLEO Pharma·Phase 2·NCT03958955·27 enrolled
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
Terminated·Amgen logoAmgen·Phase 2·NCT05591222·72 enrolled
A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Withdrawn·MMassachusetts General Hospital·Phase 2·NCT03866317
Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
Withdrawn·TThe Cleveland Clinic·Phase 2·NCT00308204
The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus
Unknown status·FFlorida Academic Dermatology Centers·Phase 2·NCT00797784·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)